D Osei-Hyiaman, J Liu, L Zhou, G Godlewski, … - The Journal of Clinical Investigation, 2008 - pubmedcentral.nih.gov Diet-induced obesity is associated with fatty liver, insulin resistance, leptin
resistance, and changes in plasma lipid profile. Endocannabinoids have been
implicated in the development of these associated phenotypes, because mice ... Cited by 30 - Related articles - All 8 versions
GG Muccioli - Chemistry and Biodiversity, 2007 - farm.ucl.ac.be The CB1 and CB2 cannabinoid receptors have been described as two prime sites of
action for endocannabinoids. Both the localization and pharmacology of these two
G-protein-coupled receptors are well-described, and numerous selective ... Cited by 17 - Related articles - View as HTML - BL Direct - All 6 versions
- ►endojournals.org AW Herling, S Kilp, R Elvert, G Haschke, W … - Endocrinology, 2008 - Endocrine Soc The CB1 receptor antagonist, rimonabant, affects the endocannabinoid system and
causes a sustained reduction in body weight (BW) despite the transient nature of
the reduction in food intake. Therefore, in a multiple-dose study, female ... Cited by 15 - Related articles - BL Direct - All 4 versions
- ►physiology.org AP Chambers, VK Vemuri, Y Peng, JAT Wood, … - … Journal of Physiology- Regulatory, Integrative and …, 2007 - Am Physiological Soc Cannabinoid (CB) 1 receptor inverse agonists inhibit food intake in animals and
humans but also potentiate emesis. It is not clear whether these effects result
from inverse agonist properties or from the blockade of endogenous ... Cited by 11 - Related articles - BL Direct - All 3 versions
F Akbas, C Gasteyger, A Sjodin, A Astrup, TM … - Obes Rev, 2008 - interscience.wiley.com The discovery of cannabinoids, with the well-known stimulatory effect of
Cannabis sativa on appetite, has offered a new drug target for obesity
treatment. Cannabinoids act on two different receptors: CB1 receptors which ... Cited by 8 - Related articles - All 5 versions
- ►bentham.org [PDF] MP Viveros, FR de Fonseca, FJ Bermudez- … - Endocrine, Metabolic &# 38; Immune Disorders-Drug …, 2008 - ingentaconnect.com 1 Departamento de Fisiologia (Fisiologia Animal II), Facultad de Biologia,
Universidad Complutense de Madrid, 28040 Madrid, Spain; 2 Fundacion IMABIS,
Hospital Carlos Haya de Malaga, Laboratorio de Medicina Regenerativa, ... Cited by 7 - Related articles - All 5 versions
I Kunz, MK Meier, A Bourson, M Fisseha, W … - International journal of obesity, 2008 - nature.com Results: Compared with vehicle-treated rats, rats administered 3 and 10 mg kg -
1 rimonabant showed an 18 and 49% increase in O 2 consumption, respectively
after 3 h. A second dose of rimonabant administered 9–14.5 h after the ... Cited by 6 - Related articles - All 5 versions
D Cota - Journal of Neuroendocrinology, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 5 - Related articles - BL Direct - All 3 versions
S Migrenne, A Lacombe, AL Lefevre, MP … - … Journal of Physiology- Regulatory, Integrative and …, 2009 - Am Physiological Soc The increase in adiponectin levels in obese patients with untreated dyslipidemia
and its mRNA expression in adipose tissue of obese animals are one of the most
interesting consequences of rimonabant treatment. Thus, part of ... Cited by 5 - Related articles - All 3 versions
- ►endocrinology-journals.org C Doyon, P Samson, J Lalonde, D Richard - Journal of Endocrinology, 2007 - Soc Endocrinology The corticotropin-releasing factor (CRF) system is involved in numerous
physiological and behavioral actions, including the regulation of energy
balance. We examined the effects of the CRF 1 receptor antagonist, ... Cited by 3 - Related articles - BL Direct - All 2 versions
